<?xml version='1.0' encoding='utf-8'?>
<document id="22045498"><sentence text="A phase I study of vinflunine in combination with capecitabine in patients with metastatic breast cancer previously treated with anthracyclines and taxanes."><entity charOffset="19-29" id="DDI-PubMed.22045498.s1.e0" text="vinflunine" /><entity charOffset="50-62" id="DDI-PubMed.22045498.s1.e1" text="capecitabine" /><entity charOffset="129-143" id="DDI-PubMed.22045498.s1.e2" text="anthracyclines" /><entity charOffset="148-155" id="DDI-PubMed.22045498.s1.e3" text="taxanes" /><pair ddi="false" e1="DDI-PubMed.22045498.s1.e0" e2="DDI-PubMed.22045498.s1.e0" /><pair ddi="false" e1="DDI-PubMed.22045498.s1.e0" e2="DDI-PubMed.22045498.s1.e1" /><pair ddi="false" e1="DDI-PubMed.22045498.s1.e0" e2="DDI-PubMed.22045498.s1.e2" /><pair ddi="false" e1="DDI-PubMed.22045498.s1.e0" e2="DDI-PubMed.22045498.s1.e3" /><pair ddi="false" e1="DDI-PubMed.22045498.s1.e1" e2="DDI-PubMed.22045498.s1.e1" /><pair ddi="false" e1="DDI-PubMed.22045498.s1.e1" e2="DDI-PubMed.22045498.s1.e2" /><pair ddi="false" e1="DDI-PubMed.22045498.s1.e1" e2="DDI-PubMed.22045498.s1.e3" /><pair ddi="false" e1="DDI-PubMed.22045498.s1.e2" e2="DDI-PubMed.22045498.s1.e2" /><pair ddi="false" e1="DDI-PubMed.22045498.s1.e2" e2="DDI-PubMed.22045498.s1.e3" /></sentence><sentence text="A phase I study was performed to determine the maximal tolerated dose (MTD), recommended dose (RD), safety and efficacy of vinflunine when combined with capecitabine in patients with metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes, with pharmacokinetic blood sampling to test potential drug-drug interactions"><entity charOffset="123-133" id="DDI-PubMed.22045498.s2.e0" text="vinflunine" /><entity charOffset="153-165" id="DDI-PubMed.22045498.s2.e1" text="capecitabine" /><entity charOffset="238-252" id="DDI-PubMed.22045498.s2.e2" text="anthracyclines" /><entity charOffset="257-264" id="DDI-PubMed.22045498.s2.e3" text="taxanes" /><pair ddi="false" e1="DDI-PubMed.22045498.s2.e0" e2="DDI-PubMed.22045498.s2.e0" /><pair ddi="false" e1="DDI-PubMed.22045498.s2.e0" e2="DDI-PubMed.22045498.s2.e1" /><pair ddi="false" e1="DDI-PubMed.22045498.s2.e0" e2="DDI-PubMed.22045498.s2.e2" /><pair ddi="false" e1="DDI-PubMed.22045498.s2.e0" e2="DDI-PubMed.22045498.s2.e3" /><pair ddi="false" e1="DDI-PubMed.22045498.s2.e1" e2="DDI-PubMed.22045498.s2.e1" /><pair ddi="false" e1="DDI-PubMed.22045498.s2.e1" e2="DDI-PubMed.22045498.s2.e2" /><pair ddi="false" e1="DDI-PubMed.22045498.s2.e1" e2="DDI-PubMed.22045498.s2.e3" /><pair ddi="false" e1="DDI-PubMed.22045498.s2.e2" e2="DDI-PubMed.22045498.s2.e2" /><pair ddi="false" e1="DDI-PubMed.22045498.s2.e2" e2="DDI-PubMed.22045498.s2.e3" /></sentence><sentence text="" /><sentence text="Sixteen patients with MBC who had received anthracyclines and taxanes in the neo/adjuvant setting, if progression occurred during or within 12 months of chemotherapy completion, and/or as first-line chemotherapy of MBC were enrolled"><entity charOffset="43-57" id="DDI-PubMed.22045498.s4.e0" text="anthracyclines" /><entity charOffset="62-69" id="DDI-PubMed.22045498.s4.e1" text="taxanes" /><pair ddi="false" e1="DDI-PubMed.22045498.s4.e0" e2="DDI-PubMed.22045498.s4.e0" /><pair ddi="false" e1="DDI-PubMed.22045498.s4.e0" e2="DDI-PubMed.22045498.s4.e1" /></sentence><sentence text=" Vinflunine (VFL) was given on day 1 with capecitabine (CAPE) twice daily from days 1 to 14, every 3 weeks"><entity charOffset="1-11" id="DDI-PubMed.22045498.s5.e0" text="Vinflunine" /><entity charOffset="13-16" id="DDI-PubMed.22045498.s5.e1" text="VFL" /><entity charOffset="42-54" id="DDI-PubMed.22045498.s5.e2" text="capecitabine" /><entity charOffset="56-60" id="DDI-PubMed.22045498.s5.e3" text="CAPE" /><pair ddi="false" e1="DDI-PubMed.22045498.s5.e0" e2="DDI-PubMed.22045498.s5.e0" /><pair ddi="false" e1="DDI-PubMed.22045498.s5.e0" e2="DDI-PubMed.22045498.s5.e1" /><pair ddi="false" e1="DDI-PubMed.22045498.s5.e0" e2="DDI-PubMed.22045498.s5.e2" /><pair ddi="false" e1="DDI-PubMed.22045498.s5.e0" e2="DDI-PubMed.22045498.s5.e3" /><pair ddi="false" e1="DDI-PubMed.22045498.s5.e1" e2="DDI-PubMed.22045498.s5.e1" /><pair ddi="false" e1="DDI-PubMed.22045498.s5.e1" e2="DDI-PubMed.22045498.s5.e2" /><pair ddi="false" e1="DDI-PubMed.22045498.s5.e1" e2="DDI-PubMed.22045498.s5.e3" /><pair ddi="false" e1="DDI-PubMed.22045498.s5.e2" e2="DDI-PubMed.22045498.s5.e2" /><pair ddi="false" e1="DDI-PubMed.22045498.s5.e2" e2="DDI-PubMed.22045498.s5.e3" /></sentence><sentence text=" Three dose levels (DL) were investigated (DL1: VFL 280 mg/m² and CAPE 1,650 mg/m²/day, DL2: VFL 320 mg/m² and CAPE 1,650 mg/m²/day and DL3: VFL 280 mg/m² and CAPE 2,000 mg/m²/day)"><entity charOffset="48-51" id="DDI-PubMed.22045498.s6.e0" text="VFL" /><entity charOffset="93-96" id="DDI-PubMed.22045498.s6.e1" text="VFL" /><entity charOffset="141-144" id="DDI-PubMed.22045498.s6.e2" text="VFL" /><entity charOffset="66-69" id="DDI-PubMed.22045498.s6.e3" text="CAPE" /><entity charOffset="111-114" id="DDI-PubMed.22045498.s6.e4" text="CAPE" /><entity charOffset="159-162" id="DDI-PubMed.22045498.s6.e5" text="CAPE" /><pair ddi="false" e1="DDI-PubMed.22045498.s6.e0" e2="DDI-PubMed.22045498.s6.e0" /><pair ddi="false" e1="DDI-PubMed.22045498.s6.e0" e2="DDI-PubMed.22045498.s6.e3" /><pair ddi="false" e1="DDI-PubMed.22045498.s6.e0" e2="DDI-PubMed.22045498.s6.e1" /><pair ddi="false" e1="DDI-PubMed.22045498.s6.e0" e2="DDI-PubMed.22045498.s6.e4" /><pair ddi="false" e1="DDI-PubMed.22045498.s6.e0" e2="DDI-PubMed.22045498.s6.e2" /><pair ddi="false" e1="DDI-PubMed.22045498.s6.e0" e2="DDI-PubMed.22045498.s6.e5" /><pair ddi="false" e1="DDI-PubMed.22045498.s6.e3" e2="DDI-PubMed.22045498.s6.e3" /><pair ddi="false" e1="DDI-PubMed.22045498.s6.e3" e2="DDI-PubMed.22045498.s6.e1" /><pair ddi="false" e1="DDI-PubMed.22045498.s6.e3" e2="DDI-PubMed.22045498.s6.e4" /><pair ddi="false" e1="DDI-PubMed.22045498.s6.e3" e2="DDI-PubMed.22045498.s6.e2" /><pair ddi="false" e1="DDI-PubMed.22045498.s6.e3" e2="DDI-PubMed.22045498.s6.e5" /><pair ddi="false" e1="DDI-PubMed.22045498.s6.e1" e2="DDI-PubMed.22045498.s6.e1" /><pair ddi="false" e1="DDI-PubMed.22045498.s6.e1" e2="DDI-PubMed.22045498.s6.e4" /><pair ddi="false" e1="DDI-PubMed.22045498.s6.e1" e2="DDI-PubMed.22045498.s6.e2" /><pair ddi="false" e1="DDI-PubMed.22045498.s6.e1" e2="DDI-PubMed.22045498.s6.e5" /><pair ddi="false" e1="DDI-PubMed.22045498.s6.e4" e2="DDI-PubMed.22045498.s6.e4" /><pair ddi="false" e1="DDI-PubMed.22045498.s6.e4" e2="DDI-PubMed.22045498.s6.e2" /><pair ddi="false" e1="DDI-PubMed.22045498.s6.e4" e2="DDI-PubMed.22045498.s6.e5" /><pair ddi="false" e1="DDI-PubMed.22045498.s6.e2" e2="DDI-PubMed.22045498.s6.e2" /><pair ddi="false" e1="DDI-PubMed.22045498.s6.e2" e2="DDI-PubMed.22045498.s6.e5" /></sentence><sentence text="" /><sentence text="The RD was established as vinflunine 280 mg/m² on day 1 plus capecitabine 1,650 mg/m²/day on days 1 to 14 given every 3 weeks"><entity charOffset="26-36" id="DDI-PubMed.22045498.s8.e0" text="vinflunine" /><entity charOffset="61-73" id="DDI-PubMed.22045498.s8.e1" text="capecitabine" /><pair ddi="false" e1="DDI-PubMed.22045498.s8.e0" e2="DDI-PubMed.22045498.s8.e0" /><pair ddi="false" e1="DDI-PubMed.22045498.s8.e0" e2="DDI-PubMed.22045498.s8.e1" /></sentence><sentence text=" Dose-limiting toxicities were grade 4 neutropenia lasting at least 7 days for 2 patients, anorexia with fatigue for 1 patient and diarrhoea with fatigue, anorexia and febrile neutropenia for 1 patient" /><sentence text=" Neutropenia was the main toxicity of the combination, it was reported in 15 patients (93" /><sentence text="8%) with grade 3 in 7 patients (43" /><sentence text="8%) and 22" /><sentence text="6% of cycles and grade 4 in 7 patients (43" /><sentence text="8%) and 19" /><sentence text="8% of cycles" /><sentence text=" Complications were rare with only one patient experiencing febrile neutropenia at DL exceeding the RD" /><sentence text=" The most frequent non-haematological toxicities were fatigue and gastrointestinal disorders; however, no grade 3 or 4 episode was observed at the RD" /><sentence text=" Hand-foot syndrome was reported in 5 patients (31" /><sentence text="3%) and 22" /><sentence text="6% of cycles, no episode of grade 3 was seen" /><sentence text=" Concerning pharmacokinetics, no modifications were detected for VFL, while slight accumulation between days 1 and 14 was observed for 5-FU formed from CAPE"><entity charOffset="135-139" id="DDI-PubMed.22045498.s21.e0" text="5-FU" /><entity charOffset="65-68" id="DDI-PubMed.22045498.s21.e1" text="VFL" /><entity charOffset="152-155" id="DDI-PubMed.22045498.s21.e2" text="CAPE" /><pair ddi="false" e1="DDI-PubMed.22045498.s21.e1" e2="DDI-PubMed.22045498.s21.e1" /><pair ddi="false" e1="DDI-PubMed.22045498.s21.e1" e2="DDI-PubMed.22045498.s21.e0" /><pair ddi="false" e1="DDI-PubMed.22045498.s21.e1" e2="DDI-PubMed.22045498.s21.e2" /><pair ddi="false" e1="DDI-PubMed.22045498.s21.e0" e2="DDI-PubMed.22045498.s21.e0" /><pair ddi="false" e1="DDI-PubMed.22045498.s21.e0" e2="DDI-PubMed.22045498.s21.e2" /></sentence><sentence text=" The risk of clinical significant drug-drug interaction was considered weak" /><sentence text=" Objective partial responses were reported in 7 patients, yielding a response rate of 43" /><sentence text="8% in the all-treated population according to the investigator assessment" /><sentence text="" /><sentence text="The combination of vinflunine and capecitabine is safe and showed promising antitumour activity in MBC patients who have failed prior anthracyclines and taxanes"><entity charOffset="19-29" id="DDI-PubMed.22045498.s26.e0" text="vinflunine" /><entity charOffset="34-46" id="DDI-PubMed.22045498.s26.e1" text="capecitabine" /><entity charOffset="134-148" id="DDI-PubMed.22045498.s26.e2" text="anthracyclines" /><entity charOffset="153-160" id="DDI-PubMed.22045498.s26.e3" text="taxanes" /><pair ddi="false" e1="DDI-PubMed.22045498.s26.e0" e2="DDI-PubMed.22045498.s26.e0" /><pair ddi="false" e1="DDI-PubMed.22045498.s26.e0" e2="DDI-PubMed.22045498.s26.e1" /><pair ddi="false" e1="DDI-PubMed.22045498.s26.e0" e2="DDI-PubMed.22045498.s26.e2" /><pair ddi="false" e1="DDI-PubMed.22045498.s26.e0" e2="DDI-PubMed.22045498.s26.e3" /><pair ddi="false" e1="DDI-PubMed.22045498.s26.e1" e2="DDI-PubMed.22045498.s26.e1" /><pair ddi="false" e1="DDI-PubMed.22045498.s26.e1" e2="DDI-PubMed.22045498.s26.e2" /><pair ddi="false" e1="DDI-PubMed.22045498.s26.e1" e2="DDI-PubMed.22045498.s26.e3" /><pair ddi="false" e1="DDI-PubMed.22045498.s26.e2" e2="DDI-PubMed.22045498.s26.e2" /><pair ddi="false" e1="DDI-PubMed.22045498.s26.e2" e2="DDI-PubMed.22045498.s26.e3" /></sentence><sentence text=" Further clinical development of this combination is warranted" /><sentence text="" /></document>